Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack drug trial halted early: Colchicine's nerve protection unproven

NCT ID NCT04420624

Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the anti-inflammatory drug colchicine could prevent nerve damage in the heart after a heart attack. About 54 adults who had a first heart attack and underwent artery-opening treatment were given colchicine or a placebo for one month. The trial was terminated early, so it is unclear if colchicine provides any benefit for this purpose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
colchicine
What this could lead to
If it had worked, this could point toward a way to reduce heart nerve damage after a heart attack.
What could go wrong
The study was terminated early with only 54 participants, so we don't have enough data to know if colchicine helps. It was also a small, early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

54 people

The number who actually took part.

Started

Dec 2020

Finished

May 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from 18 to 80 year old * Hospitalization within 12 hours of onset of acute chest pain * Patient must have suffered a documented acute myocardial infarction * Coronary occlusion on initial angiography (culprit artery with aTIMI (Thrombolysis in Myocardial Infarction) flow 1 or 0) * Patient eligible for a revascularization procedure by PTCA (Percutaneous transluminal coronary angioplasty) Exclusion Criteria: * Patients with a history of myocardial infarction prior to the current episode * Patient in cardiogenic shock or with hemodynamic instability * Patients with severe hepatic or renal dysfunction (GFR ≤30 mL/min) * Pregnant women or women of childbearing age without contraception * Treatment with a potent CYP3A4 inhibitor or a P-glycoprotein inhibitor in patients with renal or hepatic impairement * Association with macrolides (except spiramycin) * Association with pristinamycin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction, acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction heart failure myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction, acute

Contacts and locations

Locations

  • UH Montpellier

    Montpellier, 34090, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.